GlassScriptPhysician profile
Edward M Beck
NPI 1245235449
$4,745.88
in general payments reported to CMS, 2019-2025
44 companies · $572 in 2025
The $572 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,593 · 2020: $367 · 2021: $533 · 2022: $439 · 2023: $386 · 2024: $856 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,813.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $745.42 | 2019-2025 | |
| Abbvie INC. | $445.18 | 2019-2025 | |
| Astellas Pharma US INC | $374.76 | 2019-2023 | Veozah |
| Teleflex LLC | $257.47 | 2021-2025 | Urolift, Barrigel |
| Amgen INC. | $227.84 | 2019-2020 | |
| Pfizer INC. | $215.96 | 2019-2025 | |
| Tolmar, INC. | $182.38 | 2023-2025 | Jatenzo |
| Janssen Biotech, INC. | $169.00 | 2019-2025 | Erleada |
| Myovant Sciences INC. | $163.72 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $155.49 | 2021-2024 | |
| Zimmer Biomet Holdings, INC. | $149.47 | 2024 | |
| Merck Sharp & Dohme LLC | $141.51 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Endo Pharmaceuticals INC. | $137.38 | 2019-2023 | Edex, Xiaflex, Aveed |
| Sumitomo Pharma America, INC. | $123.52 | 2023-2025 | Orgovyx |
| Urogen Pharma, INC. | $114.94 | 2020-2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.